Effect of Hormonal Pre-treatment of Endometriosis on ICSI Outcome: A randomized Controlled trial

RCT preprint OA: closed CC-BY-4.0
📄 Open PDF View at publisher

Abstract

Abstract Background Endometriosis-associated infertility may compromise oocyte competence, fertilization, embryo development, and implantation. Hormonal pretreatment with dienogest has been proposed to improve the reproductive environment before intracytoplasmic sperm injection (ICSI), although evidence remains inconsistent. Objective To evaluate the effect of dienogest pretreatment on embryological and pregnancy outcomes in women with endometriosis-associated infertility undergoing their first ICSI cycle. Methods This single-center, open-label, randomized controlled trial was conducted at Kasr Al-Ainy Hospital, Cairo University, between November 2023 and April 2025. It included 86 women aged 20–40 years with endometriosis-associated infertility. Participants were allocated equally to dienogest pretreatment for 3–6 months before ICSI or to direct ICSI without hormonal pretreatment. Both groups underwent the same long gonadotrophin-releasing hormone agonist stimulation protocol. Primary outcomes were the number of retrieved oocytes, fertilization rate, and number of good-quality embryos. Secondary outcomes were biochemical and clinical pregnancy rates. Results Forty-three women were analyzed in each group, with comparable baseline demographic, hormonal, ovarian-reserve, and infertility characteristics. The mean number of retrieved oocytes did not differ significantly between groups (10.91 ± 3.06 versus 10.72 ± 2.32; p  = 0.752). Dienogest pretreatment was associated with higher numbers of metaphase-II oocytes (7.30 ± 2.16 versus 5.63 ± 1.50; p  < 0.001), two-pronuclear oocytes (4.19 ± 1.44 versus 2.84 ± 1.07; p  < 0.001), fertilization rates (56.88 ± 10.42% versus 49.35 ± 10.50%; p  = 0.001), and good-quality embryos (1.98 ± 0.94 versus 1.47 ± 0.88; p  = 0.011). Biochemical pregnancy (48.8% versus 27.9%; p  = 0.046) and clinical pregnancy (46.5% versus 23.3%; p  = 0.024) were also higher with dienogest. Conclusion Dienogest pretreatment improved oocyte maturation, fertilization, embryo quality, and early pregnancy outcomes in women without increasing total oocyte yield. Trial Registration Not applicable.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-11-22T06:15:05.045840+00:00
unpaywall
last seen: 2026-11-19T08:49:44.633026+00:00
License: CC-BY-4.0